{
    "2018-03-14": [
        [
            {
                "time": "",
                "original_text": "马云收购爱康国宾真相何在？深挖阿里和腾讯医疗的投资差异",
                "features": {
                    "keywords": [
                        "马云",
                        "收购",
                        "爱康国宾",
                        "阿里",
                        "腾讯",
                        "医疗",
                        "投资差异"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "爱康国宾私有化迷局：卖给阿里是最好的选择吗？",
                "features": {
                    "keywords": [
                        "爱康国宾",
                        "私有化",
                        "阿里",
                        "选择"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "[增持评级]医药与健康护理行业信息点评：爱康国宾私有化出现阶段性进展 阿里巴巴或为最大赢家",
                "features": {
                    "keywords": [
                        "增持评级",
                        "医药",
                        "健康护理",
                        "爱康国宾",
                        "私有化",
                        "阿里巴巴",
                        "赢家"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-14",
                "original_text": "3月14日券商晨会研报汇编",
                "features": {
                    "keywords": [
                        "券商晨会",
                        "研报汇编"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【晨会聚焦】持续看好成长和消费！ 医药行业深度：抗PD-1单抗",
                "features": {
                    "keywords": [
                        "晨会聚焦",
                        "成长",
                        "消费",
                        "医药行业",
                        "抗PD-1单抗"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-14",
                "original_text": "【医药】江琦、王超（联系人）：国务院机构改革为医药产业发展指明方向-20180314",
                "features": {
                    "keywords": [
                        "医药",
                        "国务院",
                        "机构改革",
                        "产业发展",
                        "方向"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}